Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 6, 2014

Antitope to Develop Cell Line for Baylor's Cancer Vaccine

  • British firm Antitope will be using its Composite CHO™ technology to develop a manufacturing cell line for the Baylor Institute for Immunology Research (BIIR). The cell line will be used toward production of BIIR’s dendritic-cell-targeting vaccine for treating head and neck and cervical cancer.

    Composite CHO, according to Antitope, can generate stable cell lines that can produce high yields of proteins and antibodies ready for cGMP manufacture. Gerard Zurawski, BIIR's co-director and director of its Center for Biotechnology, said in a statement that "we anticipate that the vaccine can now be rapidly advanced to clinical studies."

    Antitope and Baylor have been working together for some time: Back in January of 2010, Antitope made an agreement to apply its Composite Human Antibody™ technology to humanize several novel BIIR antibodies, which BIIR then used to develop its vaccines, including the one that is the subject of the current project.

    Antitope along with PolyTherics comprises Abzena, a company the two firms formed last month. PolyTherics purchased Antitope in July of 2013.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »